Trial Outcomes & Findings for Use of Insulin Glargine to Treat Diabetic Ketoacidosis (NCT NCT00179127)
NCT ID: NCT00179127
Last Updated: 2018-07-16
Results Overview
Unable to find any data on this study. PI left Vanderbilt and there was not a publication.
COMPLETED
NA
75 participants
Minutes
2018-07-16
Participant Flow
Original data cannot be found. PI has left Vanderbilt and does not know where records are located. Total enrollment and completion date was obtained from Institutional Review Board records.
Participant milestones
| Measure |
Glarine
glargine: 0.3u/kg of glargine, subq, once
|
Placebo
saline: 0.3cc/kg of saline, subq, once
|
|---|---|---|
|
Overall Study
STARTED
|
0
|
0
|
|
Overall Study
COMPLETED
|
0
|
0
|
|
Overall Study
NOT COMPLETED
|
0
|
0
|
Reasons for withdrawal
Withdrawal data not reported
Baseline Characteristics
Use of Insulin Glargine to Treat Diabetic Ketoacidosis
Baseline characteristics by cohort
Baseline data not reported
PRIMARY outcome
Timeframe: MinutesUnable to find any data on this study. PI left Vanderbilt and there was not a publication.
Outcome measures
Outcome data not reported
SECONDARY outcome
Timeframe: MinutesUnable to find any data on this study. PI left Vanderbilt and there was not a publication.
Outcome measures
Outcome data not reported
SECONDARY outcome
Timeframe: DaysUnable to find any data on this study. PI left Vanderbilt and there was not a publication.
Outcome measures
Outcome data not reported
Adverse Events
Glarine
Placebo
Serious adverse events
Adverse event data not reported
Other adverse events
Adverse event data not reported
Additional Information
Sheila McMorrow
Vanderbilt University Medical Center
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place